ArticleSchizophrenia (Heidelberg, Germany)2026
Post-mortem brain analysis reveals altered monoaminergic system in the dorsolateral prefrontal cortex and hippocampus in chronic schizophrenia.
Article in Schizophrenia (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Potential Role of Camel Milk in Alleviating Chronic Fatigue Syndrome in Mice: A Network Pharmacology and In Vivo Validation Study.Foods (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Schizophrenia is a multifactorial psychiatric disorder in which monoaminergic neurotransmission, particularly dopamine (DA), serotonin (5-HT), and norepinephrine (NE), is implicated in both pathophysiology and response to treatments. However, the regional composition and functional interaction among these neurotransmitters and their catabolites remain unclear. In this study, using high-performance liquid chromatography (HPLC), we quantified DA, 5-HT, NE and their metabolites, HVA, DOPAC, and 5-HIAA, along with protein levels of key monoamine-metabolizing enzymes (MAO-A, MAO-B, and COMT isoforms) in post-mortem dorsolateral prefrontal cortex (DLPFC) and hippocampus from chronic schizophrenia patients and matched healthy controls. Although absolute monoamine and enzyme levels did not differ between cases and controls, partial correlation analyses revealed remarkable schizophrenia-specific interactions. In particular, patients exhibited distinct 5-HT-DOPAC correlations in both regions, suggesting an abnormal coupling between serotonergic and dopaminergic metabolism. In the DLPFC, the DA-NE correlation was markedly attenuated in schizophrenia, potentially reflecting disrupted catecholaminergic integration relevant to cognitive function and salience processing. Furthermore, an increased 5-HIAA-5-HT correlation emerged in the hippocampus of schizophrenia patients, indicative of abnormal serotonin turnover. In conclusion, our observations indicate that while the cerebral concentrations of monoamines and their catabolites remain relatively stable in patients with schizophrenia, their interactions are significantly dysregulated compared to those reported in healthy controls. These postmortem findings provide new insights into the monoaminergic neurotransmission crosstalk in the schizophrenia brain.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.